European Journal of Biomedical and Pharmaceutical Sciences

NOVEL T-LYMPHOCYTES VACCINE CANDIDATES AGAINST HUMAN MUMPS VIRUS VIA REVERSE VACCINOLOGY

Elkhaleel Ahmed Ali Babiker, Yassir A. Almofti* and Khoubieb Ali Abd-Elrahman

ABSTRACT

Background: Mumps virus (MuV) belongs to paramyxoviridae family, genus Rubulavirus; non-segmented, enveloped negative sense single- stranded RNA virus that causes Parotitis, Viruria and Plasma viraemia. The aim of this study was to analyze Hemagglutinin Neuraminidase (HN) glycoprotein and Fusion Protein (F) of 12 mumps virus (MuV) genotypes reported in NCBI database to predict possible epitopes that can be used as a therapeutic peptides vaccine using Immune Epitope Database (IEDB). Method: A total of 593 Mumps virus (HN) glycoproteins and 58 (F) Fusion Proteins sequences were retrieved from NCBI database and aligned to obtain conserved regions. The IEDB analysis resources were used to predict B and T cells epitopes and to calculate their population coverage against the whole word. Results: no epitope was proposed as B cell epitopes from the two proteins since none of the predicted epitopes passed the threshold of Bepipred linear epitope prediction, Emini surface accessibility prediction and kolaskar & Tongaonkar antigenicity prediction tools. For HN protein four epitopes were proposed interacting with both MHCI and MHCII (558-YIMELASNI-566, 164-NMPSFIPTA-172, 554-VYCVYIMEL-562 and 555-YCVYIMELA-563). Moreover they showed high population coverage against the whole world population. The population coverage for all these four epitopes (epitope set) was 99.97%. For (F) protein, three epitopes were highly interacted with MHCI (199-YLTELTTVF207, 198LYLTELTTV206, 361-IAGSYMRRF-369). The epitope 196-LGLYLTELT-204 was only interacted with MHC class II and proposed as MHC class II epitope. The population coverage of the four epitopes of the F protein (epitope set) was 99.94%. Recommendation: This study showed that no B-cell epitopes prediction. However we proposed successful epitopes with high affinity acting as T-lymphocytes vaccine. There is no peptide vaccine has been developed for MuV. However further investigation like in vivo and in vitro studies are required to prove the effectiveness of these predicted epitopes as a peptide vaccine.

Keywords: Mumps virus, epitopes, in-silico vaccine, NCBI, IEDB.